FutureChem Co.,Ltd (220100.KQ)
KRW 20400.0
(3.61%)
KRW 20400.0
(3.61%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -591.25 Million KRW | 66.8% |
| 2022 | -8.08 Billion KRW | -148.58% |
| 2021 | 2.38 Billion KRW | -251.29% |
| 2020 | -15.46 Billion KRW | 55.91% |
| 2019 | 1.27 Billion KRW | 60.66% |
| 2018 | -7.57 Billion KRW | -56.38% |
| 2017 | -3.48 Billion KRW | -8.89% |
| 2016 | -25.9 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -517.32 Million KRW | -1467.77% |
| 2024 Q2 | -1.18 Billion KRW | -885.08% |
| 2023 FY | - KRW | 66.8% |
| 2023 Q2 | -1.23 Billion KRW | -88.6% |
| 2023 Q3 | -342.4 Million KRW | 72.31% |
| 2023 Q4 | -542.45 Million KRW | -58.43% |
| 2023 Q1 | -655.55 Million KRW | 84.03% |
| 2022 Q2 | -534.16 Million KRW | 60.43% |
| 2022 FY | - KRW | -148.58% |
| 2022 Q4 | -4.1 Billion KRW | -72.83% |
| 2022 Q3 | -2.37 Billion KRW | -344.67% |
| 2022 Q1 | -1.35 Billion KRW | -68.28% |
| 2021 Q3 | -974.97 Million KRW | 0.0% |
| 2021 Q4 | -802.28 Million KRW | 17.71% |
| 2021 FY | - KRW | -251.29% |
| 2020 FY | - KRW | 55.91% |
| 2019 FY | - KRW | 60.66% |
| 2018 FY | - KRW | -56.38% |
| 2017 FY | - KRW | -8.89% |
| 2016 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | 201.749% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | 110.569% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | 101.09% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 100.389% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 100.667% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 89.759% |
| Humedix Co., Ltd. | 54.87 Billion KRW | 101.077% |
| Boditech Med Inc. | 36.48 Billion KRW | 101.62% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 86.537% |
| Huons Co., Ltd. | 74.23 Billion KRW | 100.796% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | 104.172% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 95.453% |